

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wopto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/728,033	12/04/2003	Stephen F. Badylak	3220-73985	8358
23643 BARNES & T	7590 08/24/2005 HORNBURG LLP	EXAMINER		
11 SOUTH M		SCHUBERG, LAURA J		
INDIANAPOI	JS, IN 46204		ART UNIT	PAPER NUMBER
			1657	
			NOTIFICATION DATE	DELIVERY MODE
			08/24/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

indocket@btlaw.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/728,033	BADYLAK, STEPHEN F.	
Examiner	Art Unit	
Laura Schuberg	1657	

	Laura Schuberg	1657						
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress					
THE REPLY FILED 03 August 2009 FAILS TO PLACE THIS AF	PLICATION IN CONDITION FOR	ALLOWANCE.						
I. Material The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:								
a) The period for reply expires 4 months from the mailing date of the final rejection.								
b) The period for reply expires on: (1) the mailing date of this As no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (l)	ter than SIX MONTHS from the mailing	date of the final rejection	n.					
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1,136(a). The date have been filled is the date for purposes of determining the period of exhauster. Any CFR 1,17(a) is calculated from: (1) the expiration date of the set set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1,704(b). NOTICE OF APPEAL.	ension and the corresponding amount hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as					
The Notice of Appeal was filed on A brief in complete.	liance with 37 CER 41 37 must be	filed within two months	of the date of					
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	appeal. Since a					
<u>AMENDMENTS</u>								
 The proposed amendment(s) flide after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); 								
(c) ☐ They are not deemed to place the application in bett appeal; and/or			ne issues for					
(d) They present additional claims without canceling a c	corresponding number of finally reject	cted claims.						
NOTE: (See 37 CFR 1.116 and 41.33(a)).		affect & and and the	DTOL 004)					
 The amendments are not in compliance with 37 CFR 1.12 Applicant's reply has overcome the following rejection(s): 		mpliant Amendment (PTOL-324).					
Applicant's reply has overcome the following rejection(s): Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	nt canceling the					
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of					
Claim(s) allowed: Claim(s) objected to:								
Claim(s) rejected: 1-16. Claim(s) withdrawn from consideration:								
AFFIDAVIT OR OTHER EVIDENCE								
The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).								
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	al and/or appellant fail:	s to provide a					
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.					
 The request for reconsideration has been considered but See Continuation Sheet. 	does NOT place the application in	condition for allowan	ce because:					
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s) 13. Other:								
····								
	/Leon B Lankford/ Primary Examiner, Art U	nit 1651						

Continuation of 11. does NOT place the application in condition for allowance because: the claims remain rejected under the prior art. Applicant argues that the references do not suggest the specific element of removing endotoxins from the graft compositions and thus do not render obvious the claimed invention.

This is not found persuasive because the WO 98/25637 document specifically states that the process of removing the cellular elements from the tissue allows the preparation of a graft composition that is non-immunogenic, and thus does not induce a host immune response when implanted into a host (page 3 lines 3-10). Clearly this process would also remove any endotoxins as well as they would also elicit an immune response if left with the tissue. Applicant's disclosure also suggests that the process of removing the cellular components also removes the endotoxins as well (page 4 lines 18-25 of the as filed specification). At the very least the endotoxins would be removed upon the sterilization of the composition as taught by the WO 98/25637 (page5).

Applicant argues that the 123 patent can not be properly combined with the WO 98/25637 document because the '123 patent teaches the removal of the glycoproteins and thus teaches away from the WO 98/25637 and the current claimed invention which require glycoproteins.

This is not found persuasive because the WO 98/25637 teaches that proteins.

including glycoproteins, that facilitate cellular proliferation can be added back into the basement composition (page 11 lines 16-20). The 1/23 patent only suggests the removal of those glycoproteins that would cause an antigenic response, not that glycoproteins could not be added back in to the composition as suggested by WO

98/25637. Clearly many antigenic components (cells, glycoproteins, growth factors) are

removed during the preparation of the basement membrane and then new components added back in a form more suitable for the intended method of repair. Therefore the reference teachings are compatible for combination as the '123 patent does not require that glycoproteins that do not elicit an immune response (such as those added back into the composition as taught by Wo 90/25637) be absent from the final composition.

Applicant's arguments with regard to the double patenting rejections are identical

to those presented above and are therefore also not found persuasive as well.

Therefore the claims remain rejected as obvious over the prior art...